10x Genomics, Inc. (TXG)

Market Cap	1.33B
Revenue (ttm)	610.79M
Net Income (ttm)	-182.63M
Shares Out	122.30M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,721,213
Open	11.61
Previous Close	11.56
Day's Range	10.83 - 11.85
52-Week Range	10.80 - 48.42
Beta	1.85
Analysts	Buy
Price Target	20.36 (+86.79%)
Earnings Date	Feb 12, 2025

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as ...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Sep 12, 2019
• Employees: 1,306
• Stock Exchange: NASDAQ
• Ticker Symbol: TXG
• Website: https://www.10xgenomics.com

Financial Performance

In 2024, 10x Genomics's revenue was $610.79 million, a decrease of -1.28% compared to the previous year's $618.73 million. Losses were -$182.63 million, -28.41% less than in 2023.

Analyst Forecast

According to 16 analysts, the average rating for TXG stock is "Buy." The 12-month stock price forecast is $20.36, which is an increase of 86.79% from the latest price.

Price Target

$20.36

(86.79% upside)

Analyst Consensus: Buy